Polyomavirus (PyV) infection usually persists without any symptoms in normal individuals. In immunocompromised patients including patients with systemic lupus erythematosus (SLE), PyV reactivation occurs with a high prevalence and can cause severe clinical complications. In this study, reactivation of six PyV [JC, BK, WU, KI, merkel cell (MC) and trichodysplasia spinulosa (TS)] was investigated in terms of prevalence, clinical implications and correlation with urine transforming growth factor (TGF)-β1 expression in 50 SLE patients aged less than 18 years. Clinical characteristics were obtained from medical record review. PyV viruria was assessed by nested polymerase chain reaction. Urine TGF-β1 was measured with ELISA. The mean age was 13 ± 2.8 years. The prevalence of JC and BK viruria was 16% and 32%, respectively. WU, KI, MC and TS were not isolated from any urine specimens. Co-reactivation of 2 PyV was not detected. Urine TGF-β1 levels in patients with JC viruria, with BK viruria and without PyV viruria were 0.27 ± 0.09, 0.10 ± 0.05 and 0.13 ± 0.09 ng/mg of urine creatinine, respectively. Cumulative doses of cyclophosphamide per body weight and urine TGF-β1 levels were higher in JC viruria than in other groups (p < 0.05). The prevalence of JC and BK reactivation was higher in pediatric patients with SLE than in the normal population. JC reactivation in pediatric patients with SLE was correlated with the administration of high-dose cyclophosphamide and increased urine TGF-β1 levels. Surveillance of JC reactivation is recommended in pediatric patients with chronic and severe SLE receiving high-dose cyclophosphamide.
Polyomavirus (PyV) infections are usually acquired in early childhood. The seroprevalence of PyV infection ranges from 10% to 98% and is correlated with patient age (Stolt et al. 2003) . Although latent infection persists without symptoms after primary infection in normal individuals, severe clinical consequences such as nephropathy and progressive multifocal leukoencephalopathy from PyV reactivation may occur in immunocompromised patients (Saito et al. 1998) .
PyV reactivation in systemic lupus erythematosus (SLE) was initially reported in 1978 (Taguchi et al. 1978) . In patients with SLE, the prevalence of JC PyV (JC) reactivation is variable (Rekvig et al. 1997; Sundsfjord et al. 1999; Wang et al. 2000) whereas the prevalence of BK PyV (BK) reactivation is higher in patients with SLE than in the general population (Rekvig et al. 1997; Sundsfjord et al. 1999; Colla et al. 2007; Lu et al. 2009 ). For newly identified PyV including WU, KI, merkel cell (MC) and trichodysplasia spinulosa (TS), the prevalence of reactivation in SLE is not known.
PyV reactivation in SLE could be attributed to the combined effects of immune dysfunction and the use of immunosuppressive therapy (Sundsfjord et al. 1999) . Several immunosuppressants including cyclosporine A, tacrolimus, azathioprine and mycophenolate mofetil can increase the prevalence of BK reactivation in transplant recipients (Randhawa and Brennan 2006) . These immunosuppressants are included in the treatment regimen for severe SLE when less potent immunosuppressants fail to induce SLE remission. At the molecular level, administration of cyclosporine A and tacrolimus has been shown to increase transforming growth factor (TGF)-β1 expression (Shihab et al. 1996; Khanna et al. 1999 ). TGF-β1, an isoform of TGF-β, is involved in the regulation of cell proliferation, differentiation and immune suppression (Abend and Imperiale 2008) . In cell cultures, TGF-β1 can enhance JC and BK reactivation in human glial cells and renal tubular cells (Ravichandran et al. 2007; Abend and Imperiale 2008) . However, the role of TGF-β1 in PyV reactivation in SLE requires further investigation.
The association between PyV reactivation and SLE activity are yet to be validated. Several studies have demonstrated that a break of immunologic tolerance to selfantigens leading to the production of anti-double stranded DNA antibody (anti-dsDNA) can be induced by PyV reactivation (Flaegstad et al. 1988; Fenton et al. 2008) . The presence of anti-dsDNA is tightly correlated with SLE relapse and nephritis (Flaegstad et al. 1988) . Moreover, the incidence of thrombocytopenia and proteinuria is higher in SLE patients with BK reactivation than in those without BK reactivation (Colla et al. 2007; Lu et al. 2009 ). Thus, available evidence suggests that PyV reactivation increases activity and severity of SLE.
In this study, the reactivation of six PyV (JC, BK, WU, KI, MC and TS) in pediatric patients with SLE was investigated in terms of prevalence and clinical implications. We also studied the role of TGF-β1 in PyV reactivation in this group of patients.
Patients and Methods

Patients
Fifty patients aged less than 18 years with the diagnosis of SLE based on the 1997 American College of Rheumatology (ACR) revised criteria (Hochberg 1997) were enrolled. Patients with active SLE, acute infection or chronic kidney disease were excluded. Demographic and clinical data were obtained by medical record review. Hematological evaluation included complete blood count (CBC), serum creatinine, complement 3 and anti-dsDNA. First void midstream urine was collected from every patient. A small portion of each specimen was analyzed for urinalysis, urine protein and urine creatinine. Subsequently, urine was divided into small aliquots and stored at −80°C until analysis. The study was approved by the Institutional Review Board Committee of Faculty of Medicine, Chulalongkorn University, and complied with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects. Informed consent was obtained at the time of enrollment, and patient anonymity was preserved.
Isolation and amplification of PyV nucleic acid by nested PCR
Virus particles were separated from 10 mL of stored urine by ultracentrifugation at 4°C and 40,000 rounds per min for 3 hours using ProteomeLab TM XL-A/XL-I Protein Characterization System (Beckman Coulter Inc., Brea, CA). The PyV particles were dissolved with 500 µL of PBS/Phenol/Chloroform extraction. PyV nucleic acid was isolated from the particles using the QIAamp blood kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, and subsequently detected by nested PCR. In brief, the mixture for the first round of nested PCR included 10 µL of 2.5× Eppendorf Master Mix (Eppendorf, Hamburg, Germany), 1 µL of DNA template, 0.1 µM final concentration of each primer (Table 1) and nuclease-free water to a final volume of 25 µL. The PCR reactions were performed in a thermal cycler (Eppendorf, Hamburg, Germany) under the following conditions: initial denaturation at 94°C for 3 min, 40 cycles of amplification consisting of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min, and final extension at 72°C for 7 min. The second round of nested PCR was performed using a similar reaction mixture and thermal cycling profile as described above but changing the primer pair and using the PCR product from the first round as a template for amplification. The PCR products obtained from the second round of amplification were analyzed by 2% agarose gel electrophoresis at 100 volts, for 40 minutes. Subsequently, the agarose gel was stained with ethidium bromide and visualized under UV transillumination. The expected size of each amplified product is summarized in Table 1 .
The PCR products of interest were purified using the Perfect Prep Gel Cleanup Kit (Eppendorf, Hamburg, Germany) following the manufacturer's protocol. The purified PyV DNA was subjected to nucleotide sequence determination by a commercially available sequencing service (1st BASE Laboratories, Selangor DarulEhsan, Malaysia) and analyzed by BLAST analysis tool (http://blast.ncbi. nlm.nih.gov/Blast.cgi), BioEdit Sequence Alignment Editor version 7.0.9.0 and Chromas Lite version 2.01 (Technelysium Pty Ltd).
Measurement of urine TGF-β1 levels by ELISA
Aliquots of the first void midstream urine stored at −80°C were rapidly thawed and centrifuged at 4,000 rpm for 10 min. A 100-µL supernatant was acidified with 20 µL of 1 N HCL and left at room temperature for 10 min followed by neutralization with 20 µl of 1.2 N NaOH/0.5 M HEPES. Subsequently, the levels of TGF-β1 in the urine were measured using a commercially available ELISA kit (Quantikine ® Human TGF-β1 Immunoassay; R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Statistical Analysis
The data was analyzed using Statistical Package for the Social Sciences version 17 software (SPSS Inc., Chicago, IL), and p values of less than 0.05 were considered to be statistically significant. Descriptive data are reported using mean and standard deviation. Categorical data were compared using Fisher's exact test, and continuous variables were compared by one-way analysis of variance (ANOVA) with the Tukey HSD post-hoc test for comparisons between groups.
Results
Fifty pediatric patients (9 males, 41 females) with SLE were studied. The mean age was 13 ± 2.8 years (range 6-18 years). The duration of SLE was 1,051 ± 677 days. JC viruria was present in 8/50 (16%) whereas BK viruria was present in 16/50 (32%) of SLE patients. WU, KI, MC and TS were not isolated from any urine specimens. Co-reactivation of 2 PyV was not detected. Based on phylogenetic analysis, four of the 16 isolated BK were TU strains (Fig. 1) .
Clinical characteristics of SLE patients with JC viruria, with BK viruria and without PyV viruria are shown in Table 2 . There was no significant difference in age, hemoglobin, white blood cell counts, platelet counts, serum creatinine, complement 3, and the frequencies of pyuria or hematuria among SLE patients with JC viruria, BK viruria and no PyV viruria. The duration of the disease was significantly longer in patients with JC viruria than in the other groups (p < 0.05). Severe nephritis, defined as class 4 nephritis based on the International Society of Nephrology/ Renal Pathology Society (ISN/RPS) classification (Weening et al. 2004) , was found with a higher frequency in patients with JC viruria than in the other groups ( p < 0.05). The urine protein/creatinine ratio was higher in patients with JC viruria than in the other groups but did not reach statistical significance. The number of patients with positive antidsDNA antibody was lower in SLE patients with JC viruria than in the other groups ( p < 0.05).
Prescribed immunosuppressive regimens in these patients included prednisolone, cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine A and tacrolimus (Table 3) . One patient with JC viruria received tacrolimus and two patients with JC viruria received cyclosporine A. The cumulative dose and cumulative dose per body weight of cyclophosphamide was higher in patients with JC viruria than in the other groups ( p < 0.05) whereas the cumulative dose and cumulative dose per body weight of prednisolone, mycophenolate mofetil and azathioprine did not significantly differ between the groups (Table 3) .
The levels of TGF-β1 in the urine were reported as ng/ mg of creatinine in order to reduce the confounding effect of urine concentration on TGF-β1 measurement. Urine TGF-β1 levels were significantly higher in SLE patients with JC viruria than in the other groups ( p < 0.05) (Fig. 2) . Among patients with BK viruria, urine TGF-β1 of the four patients infected by the TU strain did not significantly differ from patients infected by the other strains (0.09 ± 0.03 vs. 0.1 ± 0.05 ng/mg of creatinine, p = 0.75).
Discussion
PyV reactivation can be determined by the presence of decoy cells, by viral proliferation from urine in cell cultures or by detection of PyV nucleic acid in the urine by PCR. In this study, PyV reactivation was determined by nested PCR, which is a sensitive and simple technique for detection of asymptomatic viruria and can identify certain types of PyV (Randhawa and Brennan 2006) . This is the first report on the prevalence of PyV reactivation in pediatric patients with SLE. The prevalence of JC and BK reactivation was higher in pediatric patients with SLE than in age-matched normal children (Zhong et al. 2007 ) but was lower than the prevalence of JC and BK reactivation in adult patients with autoimmune diseases (Wang et al. 2000; Lu et al. 2009 ). The discrepancies in the prevalence of JC and BK reactivation between different studies could be partly explained by the extent of prescribed immunosuppressive regimen and by patient age (Zhong et al. 2007) .
WU, KI, MC and TS viruria have never been reported in the general population. In this study, we could not isolate WU, KI, MC and TS from any urine samples of pediat- ric patients with SLE. By contrast, WU and KI viruria were recently reported in kidney transplant recipients (Csoma et al. 2011) . Conditions specific to the transplant process such as ischemic kidney allograft injury may increase susceptibility of transplant recipients to WU and KI reactivation. The understanding of mechanisms that induce PyV reactivation in SLE is limited. Defective cell-mediated immune response that allows PyV reactivation in patients with HIV is commonly observed in patients with SLE (Matsumoto and Hatano 1984) . In addition, T-lymphocyte functions are suppressed by the use of potent immunosuppressants to treat SLE. The combination of immune dysfunction and immunosuppressive therapy could induce JC and BK reactivation; thereby increasing the prevalence of JC and BK viruria in SLE. We did not observe the co-reactivation of JC and BK in patients with SLE although JC and BK co-reactivation was reported in patients with HIV (Nali et al. 2012) . Lack of evidence of JC and BK co-reactivation in our study suggested that the reactivation of JC and BK in SLE was regulated via different mechanisms and (50) 12 (46) Pyuria (%) 2 (13) 3 (38) 11 (42) Urine protein/creatinine ratio 1.99 ± 3.85 3.95 ± 5.91 1.73 ± 1.81
Anti-dsDNA, anti-double stranded DNA antibody. a p < 0.05 vs. BK viruria and no PyV viruria. 
Mycophenolate mofetil
Number of patients (%) 9 (56) 5 (63) 13 (50) Cumulative dose (g) 412 ± 434 500 ± 450 413 ± 428
Cumulative dose/body weight (g/kg) 9.4 ± 8.4 11.5 ± 10.6 9.5 ± 12.4
Azathioprine
Number of patients (%) 3 (19) 3 (38) 4 (15) Cumulative dose (g) 10.8 ± 5.8 17.5 ± 17.3 3.9 ± 3.5
Cumulative dose/body weight (mg/kg) 471 ± 537 654 ± 852 122 ± 118 a p < 0.05 vs. BK viruria and no PyV viruria.
may vary from the pathogenesis of PyV reactivation in HIV.
As in vitro studies have shown that TGF-β1 stimulates JC and BK reactivation in many cell cultures (Ravichandran et al. 2007; Abend and Imperiale 2008; Stettner et al. 2009 ), TGF-β1 could be an important cytokine that regulates JC and BK reactivation in SLE. TGF-β is an anti-inflammatory cytokine with three isoforms sharing similar functions namely TGF-β1 which is most abundant, TGF-β2 and TGF-β3 (Tyagi et al. 2009 ). TGF-β is produced by a variety of cells including renal epithelium, a major site of PyV reactivation (Abend and Imperiale 2008; Tyagi et al. 2009 ). Moreover, the expression of TGF-β1 is regulated by several immunosuppressants commonly prescribed in patients with SLE. Thus, we investigated the association between JC and BK reactivation and urine TGF-β1 expression in this study. Upregulation of urine TGF-β1 expression was observed in SLE patients with JC viruria but there was no significant difference between the levels of urine TGF-β1 in patients with BK viruria and no PyV viruria.
As the renal clearance of systemic TGF-β is negligible (Nowak et al. 2012) , the measurement of urine TGF-β1 reflects only the local expression of this cytokine. The increased expression of urine TGF-β1 in SLE patients with JC viruria could be explained by several mechanisms. Firstly, severe nephritis was more prevalent in SLE patients with JC viruria than in the other groups and the expression of urine TGF-β1 was increased in children with chronic glomerulonephritis (Murakami et al. 1997; Tyagi et al. 2009 ). Secondly, increased local expression of TGF-β1 has been demonstrated in tissues exposed to immunosuppressants including cyclosporine A and tacrolimus (Shihab et al. 1996; Khanna et al. 1999) . After exposure to cyclophosphamide, the local and systemic expression of TGF-β1 is different. In vivo circulating TGF-β1 levels were decreased by cyclophosphamide exposure (Mo et al. 2011) . Contrary, cyclophosphamide increased local expression of TGF-β1 in a tumor cell culture and in the urine and bladder tissue of an animal model (Kakeji et al. 1997; Tyagi et al. 2009 ).
Patients with JC viruria were prescribed with a higher cumulative dose and cumulative dose per body weight of cyclophosphamide than patients in the other groups. Upregulation of the local expression of TGF-β1 could be explained by the increased exposure to cyclophosphamide in patients with JC viruria. Although a previous study has shown that a low serum TGF-β1 level is correlated with active SLE (Becker-Merok et al. 2010) , the association between urine TGF-β1 expression and SLE activity has to be elucidated. As a starting point, this study showed that in pediatric patients with SLE, the increased cumulative doses of cyclophosphamide were associated with the upregulation of urine TGF-β1 and could influence JC reactivation. Severe complications from JC reactivation including progressive multifocal leukoencephalopathy have been reported in patients with SLE (Palazzo and Yahia 2012) . Surveillance of JC reactivation may be warranted in pediatric patients with chronic and severe SLE receiving a high cumulative dose of cyclophosphamide.
The lack of association between urine TGF-β1 and BK reactivation observed in this study is similar to the finding observed in transplant recipients (Dadhania et al. 2008) . At the molecular level, the promoter genes of various BK strains displayed different responses to the stimulation of TGF-β1. The promoter gene of the TU strain was upregulated by the presence of TGF-β1 whereas the promoter genes of Dunlop, Proto-2 and Dik strains were not (Abend and Imperiale 2008) . In our study, only four of the 16 isolated BK polyomavirus were classified as the TU strains (Fig. 1) . However, urine TGF-β1 levels in the four patients infected by the TU strains were similar to those in patients infected by the other BK strains.
The clinical implications of BK reactivation in SLE are not clearly understood. In experimental lupus-prone mice, animals with BK infection developed clinical signs of SLE earlier and more severe than those without BK infec- tion did (Fredriksen et al. 1994) . Although BK reactivation can break immunologic tolerance to autoantigens resulting in the production of autoantibodies in children and in many animal models (Flaegstad et al. 1988; Fredriksen et al. 1993; Fenton et al. 2008) , the frequency of positive antidsDNA and severe nephritis did not differ between patients with and without BK viruria in our study. The clinical significance of BK reactivation in pediatric patients with SLE requires further investigation.
In conclusion, JC and BK reactivation had a higher prevalence in pediatric patients with SLE than in the general population. As pediatric patients experience more severe SLE and usually require more intense immunosuppressive regimen than their adult counterparts (Hoffman et al. 2009 ), screening for JC and BK reactivation in this group of patients should be recommended. This study showed that JC reactivation had the tendency to occur in pediatric patients who experienced chronic and severe SLE. JC reactivation was correlated with cyclophosphamide administration and the increased expression of urine TGF-β1 in pediatric patients with SLE. As JC and BK reactivation could result in severe clinical complications in patients with SLE, monitoring of JC and BK viruria should benefit pediatric patients with chronic and severe SLE who receive intense immunosuppressive therapy.
